Lopez DL, Casillas OE, Jaramillo HJ, Romero-Garcia T, Vazquez-Jimenez JG. AT1 receptor downregulation: A mechanism for improving glucose homeostasis. World J Diabetes 2023; 14(3): 170-178 [PMID: 37035227 DOI: 10.4239/wjd.v14.i3.170]
Corresponding Author of This Article
J. Gustavo Vazquez-Jimenez, MD, PhD, Doctor, Research Scientist, Research Scientist, Faculty of Medicine, Autonomous University of Baja California, Centro Cívico, Mexicali 21000, Baja California, Mexico. gustavo.vazquez@uabc.edu.mx
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Mar 15, 2023; 14(3): 170-178 Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.170
AT1 receptor downregulation: A mechanism for improving glucose homeostasis
Diana L Lopez, Oscar E Casillas, Hiram J Jaramillo, Tatiana Romero-Garcia, J. Gustavo Vazquez-Jimenez
Diana L Lopez, Hiram J Jaramillo, Department of Internal Medicine, General Hospital of Mexicali, Mexicali 21000, Baja California, Mexico
Oscar E Casillas, J. Gustavo Vazquez-Jimenez, Faculty of Medicine, Autonomous University of Baja California, Mexicali 21000, Baja California, Mexico
Tatiana Romero-Garcia, Faculty of Sports, Autonomous University of Baja California, Mexicali 21289, Baja California, Mexico
Author contributions: Vazquez-Jimenez JG designed the research study; Lopez DL and Jaramillo HJ performed the research; Casillas OE, Romero-Garcia T, and Vazquez-Jimenez JG analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: J. Gustavo Vazquez-Jimenez, MD, PhD, Doctor, Research Scientist, Research Scientist, Faculty of Medicine, Autonomous University of Baja California, Centro Cívico, Mexicali 21000, Baja California, Mexico. gustavo.vazquez@uabc.edu.mx
Received: November 15, 2022 Peer-review started: November 15, 2022 First decision: December 26, 2022 Revised: January 13, 2023 Accepted: February 22, 2023 Article in press: February 22, 2023 Published online: March 15, 2023 Processing time: 119 Days and 18.7 Hours
Core Tip
Core Tip: Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world, whose chronic lack of control is associated with the development of several manifestations that can incapacitate the patient. Recently, it has been described that the prescription of antihypertensive drugs in the presence of proteinuria in diabetic patients can prevent kidney failure, and notably, antihypertensive drugs can also be coadjuvant to improve glucose homeostasis. In this review, we disclose the pathophysiological mechanism in which hypertension is related to the development of insulin resistance, contrasting it with the results obtained during clinical practice, giving a new approach to the use of antihypertensive drugs that beyond avoiding kidney damage, are coadjuvant in the treatment of T2DM.
